; however, new partnerships, policies, and processes are required to speed treatment by more effectively combining scientific research, commercial technologies, and private equity firm resources to accelerate the detection, diagnosis, and delivery of therapies for military patients. (6) Within the Department of Defense, the Defense Health Agency serves as the lead advocate for brain disease diagnosis and treatment for members of the Armed Forces. 3. Plan for improvements to traumatic brain injury and post-traumatic stress research Not later than 180 days after the date of the enactment of this Act, the Secretary of Defense shall submit to the congressional defense committees (as defined in section 101(a)(16) of title 10, United States Code) a report containing the following: (1) A plan— (A) for the Director of the Defense Health Agency, in collaboration with the National Institutes of Health, the Secretary of Veterans Affairs, major universities, and private firms, as appropriate, to accelerate cooperative research, development, and the fielding of breakthrough therapies for traumatic brain injury and post-traumatic stress; (B) describing actions for the Director to maximize the coordination and use of scientific research efforts carried out by other elements of the Department of Defense, the National Institutes of Health, the Secretary of Veterans Affairs, major universities, and private firms, as appropriate; (C) describing the strategy of the Department of Defense to leverage existing other transaction agreements pursuant to section 2371 of title 10, United States Code, such as the Medical Technology Enterprise Consortium of the Army, to encourage financial collaboration and accelerate breakthrough therapies for the treatment of traumatic brain injury and post-traumatic stress